ProCE Banner Activity

FAQs: Role of Immunotherapy in Biliary Tract Cancer

Clinical Thought

In this commentary, I address frequently asked questions on the current and emerging roles of immune checkpoint inhibitors in the management of patients with biliary tract cancer based on the latest available evidence.

Released: December 18, 2024

Expiration: June 17, 2025

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

Richard Kim

Richard Kim, MD

Service Chief of GI Oncology
Professor
Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca

Disclosure

Program Director

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP: researcher (paid to institution): Abgenomics, Agios, Arcus, Arys, Atreca, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Seattle Genetics; consultant (paid to institution): Arcus, Bayer, Eisai, Genentech, Incyte, Ipsen, Merck, Merck KGaA, Merus, Pfizer, Seattle Genetics, Servier; consultant: AbbVie, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Elevar, Exact Science, Exelixis, Foundation Medicine, GlaxoSmithKline, Illumina, Janssen, Kanaph, Natera, Sanofi, Sobi, Stemline, TreosBio, Xilio, Zai Labs; data and safety monitoring board: 1Globe, AstraZeneca, Exelixis, Fibrogen, Merck/Eisai, Suzhou Kintor; advisor: Artiva, Imugene, Immuneering, Replimune, Sun Biopharma, Xilis.

Lipika Goyal, MD, MPhil

Associate Professor of Medicine
Director of Gastrointestinal Medical Oncology
Stanford Cancer Center
Palo Alto, California

Lipika Goyal, MD, MPhil: researcher: Alyssum Therapeutics, Boehringer Ingelheim, Genentech; consultant: AbbVie, Agenus, Boehringer Ingelheim, Compass Therapeutics, Exelixis, Kinnate Biopharma, Merck, Relay Therapeutics, Servier, Surface Oncology, Taiho, TransThera Biosciences, Tyra Biosciences; data and safety monitoring board: AstraZeneca.

Primary Author

Richard Kim, MD

Service Chief of GI Oncology
Professor
Moffitt Cancer Center
Tampa, Florida

Richard Kim, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Eisai, Exelixis, Incyte, Jazz, Roche, Taiho, Takeda.